Last reviewed · How we verify
Relmacabtagene autoleucel and transplantation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Relmacabtagene autoleucel and transplantation (Relmacabtagene autoleucel and transplantation) — Zhengzhou University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Relmacabtagene autoleucel and transplantation TARGET | Relmacabtagene autoleucel and transplantation | Zhengzhou University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Relmacabtagene autoleucel and transplantation CI watch — RSS
- Relmacabtagene autoleucel and transplantation CI watch — Atom
- Relmacabtagene autoleucel and transplantation CI watch — JSON
- Relmacabtagene autoleucel and transplantation alone — RSS
Cite this brief
Drug Landscape (2026). Relmacabtagene autoleucel and transplantation — Competitive Intelligence Brief. https://druglandscape.com/ci/relmacabtagene-autoleucel-and-transplantation. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab